Home Cart 0 Sign in  
X

[ CAS No. 709608-85-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 709608-85-5
Chemical Structure| 709608-85-5
Chemical Structure| 709608-85-5
Structure of 709608-85-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 709608-85-5 ]

Related Doc. of [ 709608-85-5 ]

Alternatived Products of [ 709608-85-5 ]

Product Details of [ 709608-85-5 ]

CAS No. :709608-85-5 MDL No. :MFCD11052642
Formula : C8H8N2O Boiling Point : -
Linear Structure Formula :- InChI Key :LOOWJTAKSUNLSR-UHFFFAOYSA-N
M.W : 148.16 Pubchem ID :22661249
Synonyms :

Calculated chemistry of [ 709608-85-5 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.12
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 42.22
TPSA : 48.91 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.73 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.93
Log Po/w (XLOGP3) : 0.67
Log Po/w (WLOGP) : 0.9
Log Po/w (MLOGP) : 0.57
Log Po/w (SILICOS-IT) : 1.87
Consensus Log Po/w : 0.99

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.72
Solubility : 2.82 mg/ml ; 0.019 mol/l
Class : Very soluble
Log S (Ali) : -1.27
Solubility : 7.89 mg/ml ; 0.0533 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.72
Solubility : 0.282 mg/ml ; 0.00191 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.31

Safety of [ 709608-85-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 709608-85-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 709608-85-5 ]
  • Downstream synthetic route of [ 709608-85-5 ]

[ 709608-85-5 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 709608-85-5 ]
  • [ 669050-70-8 ]
YieldReaction ConditionsOperation in experiment
70%
Stage #1: With Dess-Martin periodane In tetrahydrofuran at 20℃;
Stage #2: With sodium hydrogencarbonate In tetrahydrofuran; water; ethyl acetate
Synthesis of lH-IndazoIe-4-carbaIdehyde (12i): The alcohol obtained above (54 mg, 0.36 mmol) was dissolved in 3 mL of THF, and then Dess-Martin periodinine (247 mg, 0.58 mmol) was added. The reaction mixture was stirred at room temperature overnight and quenched with Na2S2O3 (2.0 M) solution. The mixture was extracted with ethyl acetate, and the combined organic layers were combined and washed with saturated NaHCO3 solution, brine, and dried over MgSO4. Solvent was then removed and the residue was purified by column chromatography (75percent ethyl acetate/hexanes). The product (37 mg, 70percent) was obtained as a white solid. MS (ES) M+H expected = 147.1, found = 147.2
Reference: [1] Patent: WO2007/51062, 2007, A2, . Location in patent: Page/Page column 127-128
  • 2
  • [ 192945-49-6 ]
  • [ 709608-85-5 ]
YieldReaction ConditionsOperation in experiment
60%
Stage #1: With diisobutylaluminium hydride In tetrahydrofuran at 0℃;
Stage #2: With water; Rochelle's salt In tetrahydrofuran at 20℃;
Synthesis of (lH-Indazol-4-yl)-methanol (18b): The ester obtained above (40 mg, 0.23 mmol) was dissolved in 1 mL of THF and cooled to 00C. A solution of DEAL in THF (1.0 M, 2.3 mL, 2.3 mmol) was added dropwise. More DIBAL was added until the starting material disappeared. The reaction was then quenched with saturated potassium sodium tartrate solution and warmed up to room temperature. The reaction mixture was extracted with ethyl acetate. The organic layers were combined and dried over MgSO4. Solvent was then removed and the residue was purified by column chromatography (75percent ethyl acetate/hexanes). The product (20 mg, 60percent) was obtained as a white solid. MS (ES) M+H expected = 149.1, found = 149.1.
Reference: [1] Patent: WO2007/51062, 2007, A2, . Location in patent: Page/Page column 126-127
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 709608-85-5 ]

Alcohols

Chemical Structure| 478828-52-3

[ 478828-52-3 ]

(1H-Indazol-5-yl)methanol

Similarity: 0.95

Chemical Structure| 1092961-12-0

[ 1092961-12-0 ]

(1-Methyl-1H-indazol-4-yl)methanol

Similarity: 0.88

Chemical Structure| 100922-96-1

[ 100922-96-1 ]

1H-Indazol-3-ol

Similarity: 0.85

Chemical Structure| 59673-74-4

[ 59673-74-4 ]

6-Amino-1H-indazol-3-ol

Similarity: 0.84

Chemical Structure| 1092961-10-8

[ 1092961-10-8 ]

(1-Methyl-1H-indazol-6-yl)methanol

Similarity: 0.83

Related Parent Nucleus of
[ 709608-85-5 ]

Indazoles

Chemical Structure| 478828-52-3

[ 478828-52-3 ]

(1H-Indazol-5-yl)methanol

Similarity: 0.95

Chemical Structure| 1092961-12-0

[ 1092961-12-0 ]

(1-Methyl-1H-indazol-4-yl)methanol

Similarity: 0.88

Chemical Structure| 101257-89-0

[ 101257-89-0 ]

4-Methyl-1H-indazol-5-amine

Similarity: 0.86

Chemical Structure| 3176-63-4

[ 3176-63-4 ]

4-Methyl-1H-indazole

Similarity: 0.86

Chemical Structure| 100922-96-1

[ 100922-96-1 ]

1H-Indazol-3-ol

Similarity: 0.85